Browse by category

Skye Bioscience's novel CB1 antibody, nimacimab in combination with the dual GLP-1/GIP agonist, tripeptide, resulted in greater than 30%...

Tirzepatide improves kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection...

Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...

Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...

The first participant has been successfully dosed in Gan & Lee Pharmaceuticals’ Phase 2 clinical trial of bofanglutide (GZR18) injection,...

Palatin Technologies has completed its Phase 2 BMT-801 clinical study of the co-administration of MC4R bremelanotide + GLP-1/GIP...

BioAge Labs is to discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate azelaprag as monotherapy and in...

Eli Lilly and Company has announced topline results from the SURMOUNT-5 phase 3b open-label randomised clinical trial that found Zepbound...

Results from the Phase 3 SURMOUNT-1 three-year study (176-week treatment period), the longest completed study to date of tirzepatide,...

Palatin Technologies has completed enrolment in the study entitled "BMT-801, A Phase II, Randomized, Double-Blind, Placebo-Controlled,...